Merck & Co., Inc. vs Rush Street Interactive Inc — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while Rush Street Interactive Inc trades at $18.9 (market cap $2.35B). The key difference: Merck & Co., Inc. is far larger — about 149.5× Rush Street Interactive Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Rush Street Interactive Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Rush Street Interactive Inc for 13 Days on average.
| MRK | RSI | |
|---|---|---|
Market Cap | $351.28B | $2.35B |
Volume | 7,969,665 | 2,219,374 |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $34.52 |
52-Week Low | $82.49 | $15.89 |
Typical Hold Time | 98 Days | 13 Days |
Enterprise Value | $398.04B | $2.01B |
Dividend Yield | 2.39% | — |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
RSI (Rush Street Interactive) trades at $18.90, down 6.62% recently, with a bearish technical signal from moving averages. The company shows strong revenue growth from $1.13B in 2025 to $1.4B in 2026, though net income margin compressed to 2.33%. Recent Q2 2026 earnings beat expectations with EPS of $0.15 versus $0.1499 expected. Analyst consensus remains strongly bullish with 10 buy ratings and a $34.88 price target, representing 85% upside potential from current levels.
The stock presents significant upside based on analyst targets but faces execution risks amid competitive online gaming markets. High P/E ratio of 65.55 suggests premium valuation requiring sustained growth. Institutional interest remains strong with BlackRock's $448M investment in Q2 2026. Near-term performance hinges on Q3 earnings delivery and sports betting market expansion.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →